Melbourne, June 16, 2026, 05:04 (AEST).
- CSL closed off 1.84% at A$105.53. Shares moved between A$105.24 and A$108.37 for the session. Investing
- The S&P/ASX 200 outperformed, closing 1.25% higher at 8,914.00. News
- CSL’s real test comes with full-year results on August 18. Investors are watching to see if the reset is on track.
CSL Limited shares dropped again Tuesday after falling on Monday. Shares ended at A$105.53, down from A$107.51 at Friday’s close, Investing.com data shows. That comes after a short run higher—Intelligent Investor reported CSL was up 9.8% in the week to Friday. Despite the bounce, CSL is lagging in 2026 and this financial year. Investing
CSL shares moved Monday, but there’s no new strategy news in the latest company disclosures. The most recent update on CSL’s investor site is a June 9 notification of cessation of securities, and before that the May 11 interim CEO review was the last big finance item. No new headline appears to be behind the shift. The old question remains: is the CSL selloff done, or do earnings risks still weigh on the stock? Shares rise if profit or cash flow hopes pick up, and drop if investors pull back or don’t want to pay as much. CSL Limited
CSL’s overhang hasn’t cleared. Interim CEO Gordon Naylor told the May review, “Our growth initiatives are working, but the financial benefits will take longer than previously anticipated to materialise.” CSL cut its FY26 forecast, now seeing around US$15.2 billion revenue and about US$3.1 billion NPATA constant-currency. NPATA is net profit after tax, before amortisation of acquired IP and any one-offs like restructuring and impairments. The company also signalled about US$5 billion extra non-cash, pre-tax impairments across FY26 and FY27. These impairments hit reported profit but don’t affect cash in the short term.
CSL bulls say most of the bad news is priced in now. The latest Investing.com analyst poll shows consensus at Buy: 7 Buy, 9 Hold and 0 Sell out of 16. Twelve-month average target stands at A$138.36. UBS kept its Buy rating and A$158 target on June 10. Jefferies and Citi both reiterated Hold calls, with targets near where CSL trades now. Morningstar in its latest note says CSL is cheap for turnaround buyers, citing plasma demand and potential for better margins, but warns on weak pricing, plasma collection costs, and execution risk. Investing
CSL’s May update laid out why some are bearish. The firm said it lost about US$300 million from U.S. immunoglobulin channel inventory moving back to normal. Weaker albumin prices in China meant a hit of another US$200 million. On top, there was a further US$150 million drag from things like the Middle East conflict, slower HEMGENIX growth, and more iron rivals. So the stock still has turnaround risk baked in. Bulls say CSL could lift plasma margins and win back confidence, but unless August gives new detail on costs, products, impairments or the CEO handover, the risk doesn’t look low.
